Integrated BioPharma, Inc. (INBP)

Revenue by Segment

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017
Contract Manufacturing	42.39M	51.68M	48.57M	48.28M	54.09M
Other Business Lines	1.48M	2.67M	1.75M	2.40M	2.16M
Total	43.87M	54.35M	50.32M	50.67M	56.25M

Revenue by Geography

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017
United States	35.23M	43.63M	42.34M	42.62M	46.52M
International	8.64M	10.73M	7.97M	8.06M	9.73M
Total	43.87M	54.35M	50.32M	50.67M	56.25M

Data Source: S&P Global Market Intelligence Last updated: Sep 25, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 9, 2026

Data Sources Report a data error